Credit: K KStock/Adobe stock

With the arrival of Ozempic, Wegovy and other GLP-1 agonists, a weight-loss drug boom is sweeping America, bringing a new wave of hope to the almost 115 million U.S. adults and children classified as obese.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.